← FDA DRUG APPROVALS

FDA NDA · NDA008306

PHENERGAN W/ CODEINE

Sponsor: ANI PHARMS

APPLICATION
NDA008306
TYPE
NDA
ORIGINAL APPROVAL
1952-01-21
LATEST ACTION
2025-12-22
ROUTE
ORAL
DOSAGE FORM
SYRUP
MARKETING STATUS
Discontinued

Products

PHENERGAN W/ CODEINE · ReferenceDiscontinued
CODEINE PHOSPHATE 10MG/5ML, PROMETHAZINE HYDROCHLORIDE 6.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SYRUP · ORAL
PHENERGAN VC W/ CODEINE · ReferenceDiscontinued
CODEINE PHOSPHATE 10MG/5ML, PHENYLEPHRINE HYDROCHLORIDE 5MG/5ML, PROMETHAZINE HYDROCHLORIDE 6.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SYRUP · ORAL

Approval history

2025-12-22Labeling · Supplement 36 · standardLetterAP
2023-12-15Labeling · Supplement 35 · standardLabelAP
2018-06-28Labeling · Supplement 34 · standardLabelAP
2017-08-29Labeling · Supplement 33 · standardLabelAP
2017-01-13Labeling · Supplement 32 · standardLabelAP
2013-05-09Labeling · Supplement 31 · 901 requiredLetterAP
2008-11-26Labeling · Supplement 30 · standardLetterAP
2001-02-23Labeling · Supplement 29 · standardReviewAP
2000-06-23Manufacturing (CMC) · Supplement 27 · standardAP
1998-05-06Manufacturing (CMC) · Supplement 25 · standardAP
1998-02-10Manufacturing (CMC) · Supplement 24 · standardAP
1992-03-30Manufacturing (CMC) · Supplement 22 · standardAP
1989-12-12Manufacturing (CMC) · Supplement 20 · standardAP
1989-12-12Manufacturing (CMC) · Supplement 21 · standardAP
1989-01-11Labeling · Supplement 19AP
1988-06-30Manufacturing (CMC) · Supplement 18 · standardAP
1987-04-13Manufacturing (CMC) · Supplement 14 · standardAP
1986-05-29Manufacturing (CMC) · Supplement 13 · standardAP
1985-11-04Labeling · Supplement 16AP
1985-07-29Manufacturing (CMC) · Supplement 15 · standardAP
1984-04-12Labeling · Supplement 12AP
1984-04-02Manufacturing (CMC) · Supplement 10 · standardAP
1984-04-02Efficacy · Supplement 11AP
1952-01-21Type 4 - New Combination · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →